MedCity News November 12, 2024
Katie Adams

Experts agree that the incoming Trump administration will likely shake things up in the prescription drug world — most notably when it comes to research and development, drug pricing and PBM reform.

Former President Donald Trump’s return to the White House is certain to bring about changes across many facets of the healthcare sector — including reproductive care, federal insurance programs and prescription drugs.

Experts interviewed for this article, who include pharmaceutical executives and healthcare consultants, agree that the upcoming Trump administration is likely to shake things up in the prescription drug world, most notably in the areas of drug pricing, and research and development.

What effects could tariffs have on research and development?

On the campaign trail, Trump often...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Pharma, Pharma / Biotech
Related Articles:
6 key health policy areas to watch in the new year
Governing health care AI
PBM reform dropped in Congress' funding package
Trump's Picks for Top Health Jobs Not Just Team of Rivals but 'Team of Opponents'
Telehealth gets short extension, physician pay is cut in spending bill

Share This Article